pilsicainide has been researched along with Channelopathies in 1 studies
pilsicainide: structure given in first source
pilsicainide : A secondary carboxamide resulting from the formal condensation of the amino group of 2,6-dimethylaniline with the carboxy group of (tetrahydro-1H-pyrrolizin-7a(5H)-yl)acetic acid. It is a sodium channel blocker which is used as an antiarrhythmic drug for the management of atrial tachyarrhythmias in Japan.
Channelopathies: A variety of neuromuscular conditions resulting from MUTATIONS in ION CHANNELS manifesting as episodes of EPILEPSY; HEADACHE DISORDERS; and DYSKINESIAS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morita, H | 1 |
| Zipes, DP | 1 |
| Morita, ST | 1 |
| Wu, J | 1 |
1 other study available for pilsicainide and Channelopathies
| Article | Year |
|---|---|
Genotype-phenotype correlation in tissue models of Brugada syndrome simulating patients with sodium and calcium channelopathies.
Topics: Action Potentials; Adrenergic beta-Agonists; Animals; Anti-Arrhythmia Agents; Body Surface Potential | 2010 |